The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Abstract
Purpose: We investigated the effect on minimal residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included bortezomib, thalidomide, and dexamethasone (VTD) in patients with multiple myeloma (MM) responding to autologous stem-cell transplantation (auto-SCT). Patients and Methods: Patients achieving at least very good partial response who had an available molecular marker based on the immunoglobulin heavy-chain rearrangement received four courses of treatment every month: four infusions per month of bortezomib at 1.6 mg/m 2 , thalidomide at 200 mg/d, and dexamethasone at 20 mg/d on days 1 to 4, 8 to 11, and 15 to 18. Patients were studied with tumor-clone–specific primers by qualitative nested PCR and RQ-PCR. Results: Of 39 patients enrolled, 31 received the four VTD courses. Immunofixation complete responses increased from 15% after auto-SCT to 49% after VTD. Molecular remissions (MRs) were 3% after auto-SCT and 18% after VTD. Median time to maximum response was 3.5 months. So far, no patient in MR has relapsed (median follow-up, 42 months). VTD consolidation induced an additional depletion of 4.14 natural logarithms of tumor burden by RQ-PCR. Patients with a tumor load less than the median value after VTD had outcomes better than those who had tumor loads above the median value after VTD (at median follow-up: progression-free survival, 100% v 57%; P < .001). Conclusion: To the best of our knowledge, this study is the first to document the occurrence of persistent MRs in a proportion of MM patients treated without allogeneic transplantation. Moreover, the major reduction in tumor load recorded by RQ-PCR after VTD suggests that unprecedented levels of tumor cell reduction can be achieved in MM thanks to the new nonchemotherapeutic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 127
RetractedInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
(2016) · Diagnostic Pathology: Hospital Autopsy · doi:10.1016/b978-0-323-37676-1.50073-x · Cited by 1,335
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
van der Velden, V. H. J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., Flohr, T., Sutton, R., Cave, H., Madsen, H. O., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404586 · Cited by 701
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Self-citationPaiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 358
Self-citationBone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Thalidomide for treatment of multiple myeloma: 10 years later
Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117457 · Cited by 313
Self-citationCorradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M. T., Bacigalupo, A., Santoro, A., Musso, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.208 · Cited by 237
Self-citationMitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.12.025 · Cited by 211
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., et al. (2007) · Blood · doi:10.1182/blood-2006-08-042275 · Cited by 182
Self-citationSarasquete, M. E., García‐Sánz, R., González, D., Martínez‐López, J., Mateo, G., Martı́nez, P., Ribera, J., Hernández, J. M., Lahuerta, J. J., Órfão, A., et al. (2005) · PubMed · Cited by 181
Proteasome inhibitor therapy in multiple myeloma
Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P., & Anderson, K. C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0338 · Cited by 168
Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R. M., Bandini, G., Motta, M. R., Testoni, N., Amabile, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2273 · Cited by 166
Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
Ocio, E. M., Mateos, M., Maiso, P., Pandiella, A., & Miguel, J. F. S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70304-8 · Cited by 118
Davies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P., Richards, S. J., Drayson, M. T., Smith, G., Selby, P. J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02530.x · Cited by 111
Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170746 · Cited by 108
Bruno, B., Rotta, M., Patriarca, F. F., Mattei, D. G., Allione, B., Carnevale‐Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-167379 · Cited by 100
Self-citationCavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R. M., Benni, M., Pagliani, G., Bandini, G., et al. (2000) · Blood · doi:10.1182/blood.v96.1.355 · Cited by 100
Ladetto, M., Donovan, J. W., Harig, S., Weller, E. A., Trojan, A., Poor, C., Schlossman, R. L., Anderson, K. C., & Gribben, J. G. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70006-1 · Cited by 97
Self-citationBakkus, M. H. C., Bouko, Y., Samson, D., Apperley, J. F., Thielemans, K., Camp, B. V., Benner, A., Goldschmidt, H., Moos, M., & Cremer, F. W. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05120.x · Cited by 79
Moving disease biology from the lab to the clinic
Anderson, K. C. (2003) · Cancer · doi:10.1002/cncr.11137 · Cited by 70
Antiangiogenesis in haematological malignancies
Li, W. W., Hutnik, M., & Gehr, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07372.x · Cited by 67
Zangari, M., van Rhee, F., Anaissie, E. J., Pineda‐Roman, M., Haessler, J., Crowley, J. J., & Barlogie, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06982.x · Cited by 36
Chauhan, D., Li, G., Auclair, D., Hideshima, T., Podar, K., Mitsiades, N., Mitsiades, C. S., Chen, L. B., Munshi, N. C., Saxena, S. P., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000018797.66067.6c · Cited by 31
Vesole, D. H., Zhang, L., Flomenberg, N., Greipp, P. R., & Lazarus, H. M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.030 · Cited by 29
Preclinical Studies of Novel Targeted Therapies
Hideshima, T., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.013 · Cited by 28
González, D., González, M., Alonso, M. E., López‐Pérez, R., Balanzategui, A., Chillón, C., Silva, M., García‐Sánz, R., & Miguel, J. F. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402937 · Cited by 28
Palumbo, A., Falco, P., Gay, F., Montefusco, V., Crippa, C., Patriarca, F. F., Gilestro, M., Liberati, A. M., Rossini, F., Caravita, T., et al. (2008) · Blood · doi:10.1182/blood.v112.11.159.159 · Cited by 22
Self-citationLipinski, E., Cremer, F. W., Ho, A. D., Goldschmidt, H., & Moos, M. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703276 · Cited by 18
Levenga, H., Levison-Keating, S., Schattenberg, A. V. M. B., Dolstra, H., Schaap, N. P., & Raymakers, R. A. P. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705742 · Cited by 17
Ladetto, M., Mantoan, B., Marco, F. D., Drandi, D., Aguzzi, C., Astolfi, M., Vallet, S., Ricca, I., Aquila, M. D., Pagliano, G., et al. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.08.008 · Cited by 13
Self-citationIn pursuit of the allo-immune response in multiple myeloma: where do we go from here?
Cook, G., Bird, J. M., & Marks, D. I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.397 · Cited by 10
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Self-citation
Metadata
- Authors
- Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., Liberati, A. M., Caravita, T., Pisani, F., Guglielmelli, T., Callea, V., Musto, P., Cangialosi, C., Passera, R., Boccadoro, M., & Palumbo, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-20
- Volume
- 28
- Issue
- 12
- Pages
- 2077-2084
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146909892
- Cited by
- 267
- References
- 41
- FWCI
- 21.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.